Janux Therapeutics (NASDAQ:JANX) Sets New 1-Year Low – Time to Sell?

Shares of Janux Therapeutics, Inc. (NASDAQ:JANX) hit a new 52-week low during mid-day trading on Tuesday . The company traded as low as $29.51 and last traded at $30.22, with a volume of 859554 shares changing hands. The stock had previously closed at $30.64.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the stock. Leerink Partnrs raised shares of Janux Therapeutics to a “strong-buy” rating in a report on Friday, November 22nd. HC Wainwright reissued a “buy” rating and set a $70.00 target price on shares of Janux Therapeutics in a report on Monday, March 3rd. William Blair reissued an “outperform” rating on shares of Janux Therapeutics in a report on Friday, January 10th. Wedbush reissued an “outperform” rating and set a $76.00 target price (up previously from $75.00) on shares of Janux Therapeutics in a report on Friday, February 28th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $200.00 target price on shares of Janux Therapeutics in a report on Wednesday, December 11th. One research analyst has rated the stock with a hold rating, ten have given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Buy” and an average target price of $88.00.

Janux Therapeutics Stock Up 8.8 %

The firm’s 50-day moving average is $39.91 and its 200-day moving average is $47.17. The company has a market capitalization of $1.88 billion, a PE ratio of -27.19 and a beta of 3.23.

Janux Therapeutics (NASDAQ:JANX) last announced its earnings results on Thursday, February 27th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.49) by $0.13. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. As a group, equities research analysts predict that Janux Therapeutics, Inc. will post -1.38 EPS for the current year.

Insider Buying and Selling

In other Janux Therapeutics news, Director Ra Capital Management, L.P. purchased 341,742 shares of the business’s stock in a transaction on Wednesday, March 5th. The stock was acquired at an average cost of $30.64 per share, for a total transaction of $10,470,974.88. Following the completion of the transaction, the director now directly owns 9,658,988 shares in the company, valued at approximately $295,951,392.32. This represents a 3.67 % increase in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO David Alan Campbell sold 25,000 shares of the company’s stock in a transaction dated Tuesday, December 24th. The shares were sold at an average price of $56.19, for a total transaction of $1,404,750.00. Following the sale, the chief executive officer now owns 217,054 shares of the company’s stock, valued at approximately $12,196,264.26. The trade was a 10.33 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 50,002 shares of company stock worth $2,684,703. Corporate insiders own 29.40% of the company’s stock.

Institutional Trading of Janux Therapeutics

Several institutional investors have recently added to or reduced their stakes in JANX. Plato Investment Management Ltd boosted its position in Janux Therapeutics by 18.7% during the third quarter. Plato Investment Management Ltd now owns 1,186 shares of the company’s stock valued at $54,000 after buying an additional 187 shares during the period. Russell Investments Group Ltd. boosted its holdings in shares of Janux Therapeutics by 77.7% during the fourth quarter. Russell Investments Group Ltd. now owns 1,011 shares of the company’s stock worth $54,000 after purchasing an additional 442 shares during the period. GF Fund Management CO. LTD. purchased a new stake in shares of Janux Therapeutics during the fourth quarter worth about $59,000. Avanza Fonder AB purchased a new stake in shares of Janux Therapeutics during the fourth quarter worth about $139,000. Finally, Meeder Asset Management Inc. purchased a new stake in shares of Janux Therapeutics during the fourth quarter worth about $159,000. 75.39% of the stock is currently owned by hedge funds and other institutional investors.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.